Galderma Reports Nearly 25% Growth Amid Botox Demand Increase
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowCEO Flemming Ørnskov announced that Galderma has seen nearly 25% sales growth year-on-year at constant currencies, attributed to the rising use of GLP-1 weight-loss drugs like Ozempic. Approximately one in 10 U.S. adults are now using these medications, creating strong demand for Galderma’s aesthetic products to combat facial volume loss associated with significant weight loss, informally known as 'Ozempic face.' Growth in the U.S. market was particularly notable at 32%, compared to 19% worldwide. This trend in increasing demand for cosmetic injectables may impact Galderma's market presence positively moving forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
